<SEC-DOCUMENT>0001213900-25-043211.txt : 20250514
<SEC-HEADER>0001213900-25-043211.hdr.sgml : 20250514
<ACCEPTANCE-DATETIME>20250514145940
ACCESSION NUMBER:		0001213900-25-043211
CONFORMED SUBMISSION TYPE:	SCHEDULE 13D
PUBLIC DOCUMENT COUNT:		2
FILED AS OF DATE:		20250514
DATE AS OF CHANGE:		20250514

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Alaunos Therapeutics, Inc.
		CENTRAL INDEX KEY:			0001107421
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				841475642
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-79364
		FILM NUMBER:		25944714

	BUSINESS ADDRESS:	
		STREET 1:		2617 BISSONNET ST
		STREET 2:		SUITE 233
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77005
		BUSINESS PHONE:		(346) 355-4099

	MAIL ADDRESS:	
		STREET 1:		2617 BISSONNET ST
		STREET 2:		SUITE 233
		CITY:			HOUSTON
		STATE:			TX
		ZIP:			77005

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ZIOPHARM ONCOLOGY INC
		DATE OF NAME CHANGE:	20050919

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	EASYWEB INC
		DATE OF NAME CHANGE:	20010213

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			PMGC CAPITAL LLC
		CENTRAL INDEX KEY:			0002068010
		ORGANIZATION NAME:           	
		EIN:				331978501
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D

	BUSINESS ADDRESS:	
		STREET 1:		120 NEWPORT CENTER DRIVE
		STREET 2:		STE. 250
		CITY:			NEWPORT BEACH
		STATE:			CA
		ZIP:			92660
		BUSINESS PHONE:		888-445-4886

	MAIL ADDRESS:	
		STREET 1:		120 NEWPORT CENTER DRIVE
		STREET 2:		STE. 250
		CITY:			NEWPORT BEACH
		STATE:			CA
		ZIP:			92660
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13D
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13D" xmlns:com="http://www.sec.gov/edgar/common">
  <headerData>
    <submissionType>SCHEDULE 13D</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <!-- Field: Pseudo-Tag; ID: Name; Data: PMGC CAPITAL LLC -->
          <cik>0002068010</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <securitiesClassTitle>Common Stock</securitiesClassTitle>
      <dateOfEvent>05/12/2025</dateOfEvent>
      <previouslyFiledFlag>false</previouslyFiledFlag>
      <issuerInfo>
        <issuerCIK>0001107421</issuerCIK>
        <issuerCUSIP>98973P309</issuerCUSIP>
        <issuerName>Alaunos Therapeutics, Inc.</issuerName>
        <address>
          <com:street1>2617 Bissonnet, Suite 233,</com:street1>
          <com:city>Houston</com:city>
          <com:stateOrCountry>TX</com:stateOrCountry>
          <com:zipCode>77005</com:zipCode>
        </address>
      </issuerInfo>
      <authorizedPersons>
        <notificationInfo>
          <personName>Ross D. Carmel, Esq.</personName>
          <personPhoneNum>2126580458</personPhoneNum>
          <personAddress>
            <com:street1>Sichenzia Ross Ference Carmel LLP,</com:street1>
            <com:street2>1185 Avenue of the Americas, 31st Floor</com:street2>
            <com:city>New York</com:city>
            <com:stateOrCountry>NY</com:stateOrCountry>
            <com:zipCode>10036</com:zipCode>
          </personAddress>
        </notificationInfo>
      </authorizedPersons>
    </coverPageHeader>
    <reportingPersons>
      <reportingPersonInfo>
        <reportingPersonCIK>0002068010</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>PMGC CAPITAL LLC</reportingPersonName>
        <fundType>WC</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>NV</citizenshipOrOrganization>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>83500.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>83500.00</sharedDispositivePower>
        <aggregateAmountOwned>83500.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>5.09295</percentOfClass>
        <typeOfReportingPerson>OO</typeOfReportingPerson>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonCIK>0001840563</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>PMGC Holdings Inc.</reportingPersonName>
        <fundType>AF</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>NV</citizenshipOrOrganization>
        <soleVotingPower>0.00</soleVotingPower>
        <sharedVotingPower>83500.00</sharedVotingPower>
        <soleDispositivePower>0.00</soleDispositivePower>
        <sharedDispositivePower>83500.00</sharedDispositivePower>
        <aggregateAmountOwned>83500.00</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>5.09295</percentOfClass>
        <typeOfReportingPerson>CO</typeOfReportingPerson>
        <commentContent>PMGC Holdings Inc. is the sole member of PMGC Capital LLC and exercises voting and dispositive control over the common stock of Alaunos Therapeutics, Inc. held in the name of PMGC Capital LLC.</commentContent>
      </reportingPersonInfo>
    </reportingPersons>
    <items1To7>
      <item1>
        <securityTitle>Common Stock</securityTitle>
        <issuerName>Alaunos Therapeutics, Inc.</issuerName>
        <issuerPrincipalAddress>
          <com:street1>2617 Bissonnet, Suite 233,</com:street1>
          <com:city>Houston</com:city>
          <com:stateOrCountry>TX</com:stateOrCountry>
          <com:zipCode>77005</com:zipCode>
        </issuerPrincipalAddress>
      </item1>
      <item2>
        <filingPersonName>This Schedule 13D is filed on behalf of PMGC Capital LLC ("PMGC LLC"). PMGC Holdings Inc. ("PMGC Holdings") is the sole member of PMGC LLC and exercises voting and dispositive control over the common stock held in the name of PMGC LLC.</filingPersonName>
        <principalBusinessAddress>The principal business address of PMGC LLC is 120 Newport Center Drive, Ste. 249, Newport Beach, California 92660.</principalBusinessAddress>
        <principalJob>PMGC LLC is a multi-strategy investment firm focused on direct investments, strategic lending, and acquiring undervalued companies and assets across diverse markets. PMGC LLC is a wholly-owned subsidiary of PMGC Holdings.</principalJob>
        <hasBeenConvicted>During the last five years, neither PMGC LLC nor PMGC Holdings has been convicted in a criminal proceeding (excluding traffic violations or similar misdemeanors).</hasBeenConvicted>
        <convictionDescription>During the last five years, neither PMGC LLC nor PMGC Holdings has been a party to a civil proceeding of a judicial or administrative body of competent jurisdiction which resulted in a judgment, decree or final order enjoining future violations of, or prohibiting or mandating activities subject to, federal or state securities laws or finding any violation with respect to such laws.</convictionDescription>
        <citizenship>PMGC LLC is organized under the laws of Nevada.</citizenship>
      </item2>
      <item3>
        <fundsSource>The aggregate purchase price of the 83,500 shares of Common Stock beneficially owned by PMGC LLC was approximately $217,094.38.  PMGC LLC used its working capital as the source of funds to purchase these shares.</fundsSource>
      </item3>
      <item4>
        <transactionPurpose>PMGC LLC acquired shares of Alaunos Therapeutics, Inc.'s (the "Issuer") common stock based on its belief that these common stock represent an attractive investment opportunity. The following information may be deemed pertinent. PMGC Capital intends to engage constructively with the Issuer's  management and board of directors to explore strategic opportunities, including potential mergers, acquisitions or partnerships. Depending on its assessment of various factors, PMGC LLC may, from time to time, modify its present intention as stated in this Item 4.

Other than as described herein, or as described under Item 5 below, PMGC LLC does not currently have plans or proposals that relate to or would result in any of the transactions involving the Issuer described in subparagraphs (a) through (j) of Item 4 of Schedule 13D (although PMGC LLC may from time to time consider pursuing or proposing any such transactions and, in that connection, may discuss, evaluate and/or pursue any such transactions with their respective advisors, the Issuer or other persons).</transactionPurpose>
      </item4>
      <item5>
        <percentageOfClassSecurities>PMGC LLC beneficially owns 83,500 shares of common stock, which represents 5.09295% of the Issuer's common stock, based on 1,639,521 issued and outstanding shares of the Issuer as of May 5, 2025, as reported in its Preliminary Schedule 14A filed with the U.S. Securities and Exchange Commission on May 9, 2025. PMGC Inc. is the sole member of PMGC LLC and exercises voting and dispositive control over the Issuer's common stock held in the name of PMGC LLC.</percentageOfClassSecurities>
        <numberOfShares>PMGC LLC beneficially owns 83,500 shares of the Issuer's common stock and exercises voting and dispositive control over such common stock. PMGC Holdings is the sole member of PMGC LLC and exercises voting and dispositive control over the common stock held in the name of PMGC LLC.</numberOfShares>
        <transactionDesc>Between May 2, 2025 and May 12, 2025, PMGC LLC purchased, on the open market, 83,500 shares of the the Issuer's common stock at prices ranging between $2.49 to $2.99.</transactionDesc>
        <listOfShareholders>Not applicable.</listOfShareholders>
        <date5PercentOwnership>Not applicable.</date5PercentOwnership>
      </item5>
      <item6>
        <contractDescription>Joint Filing Agreement between PMGC LLC and PMGC Holdings dated May 14, 2025.</contractDescription>
      </item6>
      <item7>
        <filedExhibits>See Joint Filing Agreement filed as Exhibit 99.1.</filedExhibits>
      </item7>
    </items1To7>
    <signatureInfo>
      <signaturePerson>
        <signatureReportingPerson>PMGC CAPITAL LLC</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Graydon Bensler</signature>
          <title>Graydon Bensler, Manager of PMGC Capital LLC</title>
          <date>05/14/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>PMGC Holdings Inc.</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Graydon Bensler</signature>
          <title>Graydon Bensler, Chief Executive Officer of PMGC Holdings Inc.</title>
          <date>05/14/2025</date>
        </signatureDetails>
      </signaturePerson>
    </signatureInfo>
  </formData>

</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ea024218501ex99-1_alaunos.htm
<DESCRIPTION>JOINT FILING AGREEMENT
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>Exhibit 99.1</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>JOINT FILING AGREEMENT</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><B>&nbsp;</B></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">This Joint Filing Agreement, dated May 14, 2025,
is entered into by and between PMGC Capital LLC, a Nevada limited liability company, and PMGC Holdings, Inc., a Nevada corporation (collectively
referred to herein as (the &ldquo;Filers&rdquo;). Each of the Filers may be required to file with the U.S. Securities and Exchange Commission
a statement on Schedule 13D with respect to shares of common stock, $0.001 par value per share, of Alaunos Therapeutics, Inc. beneficially
owned by them from time to time. Pursuant to and in accordance with Rule 13(d)(1)(k) promulgated under the Securities Exchange Act of
1934, as amended, the Filers hereby agree to file a single statement on Schedule 13G and/or 13D (and any amendments thereto) on behalf
of each of such parties, and hereby further agree to file this Joint Filing Agreement as an exhibit to such statement, as required by
such rule. This Joint Filing Agreement may be terminated by any of the Filers upon one week&rsquo;s prior written notice or such lesser
period of notice as the Filers may mutually agree.</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">May 14, 2025</FONT></TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>PMGC CAPITAL LLC</B></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD>
    <TD>&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/ Graydon Bensler </I></FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name:&nbsp;</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Graydon Bensler </FONT></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title:</FONT></TD>
    <TD><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Manager </FONT></TD></TR>
</TABLE>

<P STYLE="margin: 0">&nbsp;</P>

<P STYLE="margin: 0"></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2"><B>PMGC Holdings Inc.</B></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD STYLE="width: 60%">&nbsp;</TD>
    <TD STYLE="width: 5%">&nbsp;</TD>
    <TD STYLE="width: 35%">&nbsp;</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD COLSPAN="2" STYLE="border-bottom: black 1.5pt solid"><I>/s/ Graydon Bensler</I></TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Name:&nbsp;</TD>
    <TD>Graydon Bensler</TD></TR>
  <TR STYLE="vertical-align: top">
    <TD>&nbsp;</TD>
    <TD>Title:</TD>
    <TD>Chief Executive Officer</TD></TR>
  </TABLE>

<P STYLE="margin: 0">&nbsp;</P>


<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0">&nbsp;</P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
